In clinical practice, if there is a need to use hypoglycaemic agents in people with diabetes and ESKD, such as insulin and/or sulfonylureas, including in combination with incretin therapy, it is recommended to use a CGM to monitor for glycaemic excursions in real time, especially given the proven benefits of CGMs in preventing hypoglycaemic events with the use of predictive low glucose alerts [18]. Here, INS is linked to diabetes mellitus.